Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer

Toàn, Nguyễn Lĩnh; Hang, Ngo Thu; Luu, Nguyen Kim; Mao, Can Van; Ba, Nguyen Van; Xuân, Nguyễn Thị; Cam, Truong Dinh; Yamamoto, Naoki; Tong, Hoang Van; Sơn, Hồ Anh

doi:10.21873/anticanres.13521

Cited by 6 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hep2 laryngeal cancer cells treated with MeV and nimotuzumab had a significantly lower survival rate compared to those treated with MeV or nimotuzumab alone (p<0.0001). Mice bearing Hep2 human laryngeal tumors had a higher survival rate when treated with intratumoral MeV and/or nimotuzumab (6/10) then those untreated (2/10), and the survival rate of the group treated with MeV and nimotuzumab was higher compared to the groups receiving single treatment ( 125 ).…”

Section: Measles Vaccinementioning

confidence: 98%

Repurposing Infectious Diseases Vaccines Against Cancer

et al. 2021

View full text Add to dashboard Cite

Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research.

show abstract

Section: Measles Vaccinementioning

confidence: 98%

Repurposing Infectious Diseases Vaccines Against Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…10 5 TCID50 2.5 ± 0.41 (4) 2.2 ± 0.18 (4) 2.5 ± 0.29 (4) 2.4 ± 0.40 (4) 2.4 ± 0.41 (4) 3.1 (2) 10 6 TCID50 2.2 ± 0.13 (4) 2.3 ± 0.13 (4) 2.3 ± 0.16 (4) 2.3 ± 0.26 (4) 2.4 ± 0.22 (4) 2.9 (2)…”

Section: The Presence Of Measles Virus In Plasma and Tissuesmentioning

confidence: 99%

“…These results indicate that the monkeys were infected with MeV, and the viruses circulated for one month after the infection. 2.2 ± 0.18 (4) 2.3 ± 0.17 (4) 2.4 ± 0.10 (4) 2.4 ± 0.08 (4) 2.6 (2)…”

Section: The Presence Of Measles Virus In Plasma and Tissuesmentioning

confidence: 99%

“…The vaccine strain of the measles virus (MeV) is one of the most highly effective OLVs for cancer treatment. MeV has previously been shown to have a great anticancer property in small animal models against different cancers such as laryngeal cancer 4 , human solid malignancies 5 , and human hematological cancers 6 . However, the MeV dose required for cancer treatment is much higher than that used for vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical toxicological evaluation of measles virus vaccine strain in non-human primates: A two-month intravenous study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: Based on its ability to kill tumor cells, the vaccine strain of the measles virus is used for oncolytic virotherapy. However, the dose required for cancer therapy is much higher than that used for vaccination. Therefore, this study was conducted to evaluate the preclinical toxicology of the vaccine strain of measles virus in monkeys. Methods: 16 healthy Macaca mulata monkeys were randomly divided into four groups, of which one was a control. A preclinical safety evaluation of the vaccine strain of the measles virus was performed, and the three experimental groups were intravenously injected with the strain at doses of 105 TCID50, 106 TCID50 and 107 TCID50 respectively. Results: There were no significant abnormalities in the physical, clinical, haematological, and biochemical parameters following the intravenous injection with measles vaccine at doses of 105 TCID50, 106 TCID50 and 107 TCID50. The vaccine strain of measles virus remained in the plasma until the 30th day and disappeared on the 60th, and it did not persist in the tissues on days 30 and 60 post injection. Measles IgG antibody was negative on days 0, 1, 3, and 8 and was positive on days 15, 30, and 60 post administration of the measles virus. The histopathology of target organs was not affected in all groups on days 30 and 60 post injection. Conclusions: The systematic preclinical safety data of the present study confirms the safety of two months of concentrated measles vaccine administration in the Macaca mulata monkey for clinical trials.

show abstract

“…Genetically engineered onclytic viruses (OVs) can infect cancer cells. After infection, OVs can only replicate in cancer cells and induce viral oncolysis [5][6][7][8][9][10]. Among many types of OVs, oncolytic herpes simplex viruses (oHSVs) have raised the possibility for clinical application of oncolytic virotherapy [11].…”

Section: Introductionmentioning

confidence: 99%

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

et al. 2021

View full text Add to dashboard Cite

Oncolytic virotherapy is an encouraging treatment using herpes simplex virus (HSV) for gastric cancer patients. To treat gastric cancer, we generated and evaluated the efficacy of an attractive type of oncolytic HSV expressing the suppressor of cytokine signaling 3 (SOCS3). We constructed a third-generation type of oncolytic HSV (T-SOCS3) arming with SOCS3 by a bacterial artificial chromosome (BAC) system. We examined the viral replicative intensification and oncolysis of T-SOCS3 for human gastric cancer cell lines ex vivo. T-SOCS3 enhanced its replication and potentiated its cell-killing effect for MKN1 human gastric cancer cell lines, which are resistant to a non-armed third-generation type of oncolytic HSV (T-01) ex vivo. T-SOCS3 also induced the destruction within human gastric cancer specimens. Armed oncolytic HSVs expressing SOCS3 may be an efficacious therapeutic agent for gastric cancer treatment.

show abstract

Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer

Cited by 6 publications

References 30 publications

Repurposing Infectious Diseases Vaccines Against Cancer

Repurposing Infectious Diseases Vaccines Against Cancer

Preclinical toxicological evaluation of measles virus vaccine strain in non-human primates: A two-month intravenous study

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

Contact Info

Product

Resources

About